Business Summary
- Service: discovery, identification and selection of new therapeutic targets in oncology;
- Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships;
- Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology.
60.3% of sales are abroad.
Number of employees: 236
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fabrice Viviani
CEO | Chief Executive Officer | - | - |
Arnaud Lafforgue
DFI | Director of Finance/CFO | - | 31/12/17 |
Stéphane Gerart
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/19 |
Jan Hoflack
CTO | Chief Tech/Sci/R&D Officer | 63 | 31/12/08 |
Karine Lignel
BRD | Director/Board Member | 55 | 13/05/08 |
General Counsel | - | 30/04/21 | |
Thierry Billoué
HRO | Human Resources Officer | - | 31/01/17 |
62 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kamel Besseghir
BRD | Director/Board Member | 75 | 02/02/14 |
62 | - | ||
Karine Lignel
BRD | Director/Board Member | 55 | 13/05/08 |
Fabrice Viviani
CEO | Chief Executive Officer | - | - |
Aline Aubertin
BRD | Director/Board Member | - | 23/06/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,848,412 | 730,880 ( 10.67 %) | 0 | 10.67 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Pharmaceuticals: Major
|
Sector
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |